Alavian S M et al. P, et al. Occult lifelong persistence of infectious hepadnavirus and residual liver inflammation in woodchucks convalescent from acute viral hepatitis. Hepatology. 1999;29(3):928-38. 71. Korba BE, Wells FV, Baldwin B, Cote PJ, Tennant BC, Popper H, et al. Hepatocellular carcinoma in woodchuck hepatitis virus-in- fected woodchucks: presence of viral DNA in tumor tissue from chronic carriers and animals serologically recovered from acute infections. Hepatology. 1989;9(3):461-70. 72. Miura Y, Shibuya A, Adachi S, Takeuchi A, Tsuchihashi T, Naka- zawa T, et al. Occult hepatitis B virus infection as a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C in whom viral eradication fails. Hepatol Res. 2008;38(6):546-56. 73. Squadrito G, Pollicino T, Cacciola I, Caccamo G, Villari D, La Masa T, et al. Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients. Cancer. 2006;106(6):1326-30. 74. Hasegawa I, Orito E, Tanaka Y, Hirashima N, Sakakibara K, Saku- rai M, et al. Impact of occult hepatitis B virus infection on effi- cacy and prognosis of interferon-alpha therapy for patients with chronic hepatitis C. Liver Int. 2005;25(2):247-53. 75. Pollicino T, Raffa G, Costantino L, Lisa A, Campello C, Squadrito G, et al. Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma. Hep- atology. 2007;45(2):277-85. 76. Chen BF, Liu CJ, Jow GM, Chen PJ, Kao JH, Chen DS. High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases. Gastroenterology. 2006;130(4):1153-68. 77. Kusakabe A, Tanaka Y, Orito E, Sugauchi F, Kurbanov F, Sakamoto T, et al. A weak association between occult HBV infection and non-B non-C hepatocellular carcinoma in Japan. J Gastroenterol. 2007;42(4):298-305. 78. Tamori A, Nishiguchi S, Kubo S, Enomoto M, Koh N, Takeda T, et al. Sequencing of human-viral DNA junctions in hepatocellular carcinoma from patients with HCV and occult HBV infection. J Med Virol. 2003;69(4):475-81. 79. Cortelezzi A, Vigano M, Zilioli VR, Fantini NN, Pasquini MC, Deliliers GL, et al. Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H. J Clin Virol. 2006;35(4):467-9. 80. Chen MH, Hsiao LT, Chiou TJ, Liu JH, Gau JP, Teng HW, et al. High prevalence of occult hepatitis B virus infection in patients with B cell non-Hodgkin’s lymphoma. Ann Hematol. 2008;87(6):475-80. 81. Ferraro D, Pizzillo P, Di Marco V, Vultaggio A, Iannitto E, Venezia G, et al. Evaluating the risk of hepatitis B reactivation in patients with haematological malignancies: is the serum hepatitis B vi- rus profile reliable? Liver Int. 2009;29(8):1171-7. 82. Fukushima N, Mizuta T, Tanaka M, Yokoo M, Ide M, Hisatomi T, et al. Retrospective and prospective studies of hepatitis B virus re- activation in malignant lymphoma with occult HBV carrier. Ann Oncol. 2009;20(12):2013-7. 83. Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg- negative patients undergoing cytotoxic chemotherapy. Gastro- enterology. 2006;131(1):59-68. 84. Cheung WI, Chan HL, Leung VK, Tse CH, Fung K, Lin SY, et al. Reac- tivation of hepatitis B virus infection with persistently negative HBsAg on three HBsAg assays in a lymphoma patient undergo- ing chemotherapy. J Clin Virol. 2010;47(2):193-5. 85. Zhang B, Wang J, Xu W, Wang L, Ni W. Fatal reactivation of oc- cult hepatitis B virus infection after rituximab and chemother- apy in lymphoma: necessity of antiviral prophylaxis. Onkologie. Occult Hepatitis B (OBH) in Clinical Settings 2010;33(10):537-9. 86. Hui CK, Cheung WW, Leung KW, Cheng VC, Tang BS, Li IW, et al. Retracted: outcome and immune reconstitution of HBV-specific immunity in patients with reactivation of occult HBV infection after alemtuzumab-containing chemotherapy regimen. Hepatol- ogy. 2008;48(2):1-10. 87. Iannitto E, Minardi V, Calvaruso G, Mule A, Ammatuna E, Di Tra- pani R, et al. Hepatitis B virus reactivation and alemtuzumab therapy. Eur J Haematol. 2005;74(3):254-8. 88. Chung SJ, Kim JK, Park MC, Park YB, Lee SK. Reactivation of hepa- titis B viral infection in inactive HBsAg carriers following anti-tu- mor necrosis factor-alpha therapy. J Rheumatol. 2009;36(11):2416- 20. 89. Wendling D, Di Martino V, Prati C, Toussirot E, Herbein G. Spondy- loarthropathy and chronic B hepatitis. Effect of anti-TNF therapy. Joint Bone Spine. 2009;76(3):308-11. 90. Grumayer ER, Panzer S, Ferenci P, Gadner H. Recurrence of hepa- titis B in children with serologic evidence of past hepatitis B vi- rus infection undergoing antileukemic chemotherapy. J Hepatol. 1989;8(2):232-5. 91. Xunrong L, Yan AW, Liang R, Lau GK. Hepatitis B virus (HBV) reac- tivation after cytotoxic or immunosuppressive therapy--patho- genesis and management. Rev Med Virol. 2001;11(5):287-99. 92. Angus PW. Review: hepatitis B and liver transplantation. J Gastro- enterol Hepatol. 1997;12(3):217-23. 93. Ghisetti V, Marzano A, Zamboni F, Barbui A, Franchello A, Gaia S, et al. Occult hepatitis B virus infection in HBsAg negative pa- tients undergoing liver transplantation: clinical significance. Liver Transpl. 2004;10(3):356-62. 94. Uemoto S, Sugiyama K, Marusawa H, Inomata Y, Asonuma K, Egawa H, et al. Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants. Transplantation. 1998;65(4):494-9. 95. Prieto M, Gomez MD, Berenguer M, Cordoba J, Rayon JM, Pastor M, et al. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. Liver Transpl. 2001;7(1):51-8. 96. Hussain M, Soldevila-Pico C, Emre S, Luketic V, Lok AS. Presence of intrahepatic (total and ccc) HBV DNA is not predictive of HBV re- currence after liver transplantation. Liver Transpl. 2007;13(8):1137- 44. 97. Roche B, Feray C, Gigou M, Roque-Afonso AM, Arulnaden JL, Delvart V, et al. HBV DNA persistence 10 years after liver trans- plantation despite successful anti-HBS passive immunoprophy- laxis. Hepatology. 2003;38(1):86-95. 98. Shetty K, Hussain M, Nei L, Reddy KR, Lok AS. Prevalence and sig- nificance of occult hepatitis B in a liver transplant population with chronic hepatitis C. Liver Transpl. 2008;14(4):534-40. 99. Ciesek S, Helfritz FA, Lehmann U, Becker T, Strassburg CP, Neipp M, et al. Persistence of occult hepatitis B after removal of the hepatitis B virus-infected liver. J Infect Dis. 2008;197(3):355-60. 100. Kempinska A, Kwak EJ, Angel JB. Reactivation of hepatitis B in- fection following allogeneic bone marrow transplantation in a hepatitis B-immune patient: case report and review of the litera- ture. Clin Infect Dis. 2005;41(9):1277-82. 101. Lau GK. Hepatitis B reactivation after chemotherapy: two de- cades of clinical research. Hepatol Int. 2008;2(2):152-62. 102. Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil thera- py. Gastroenterology. 2004;126(7):1750-8. 8 Published by Kowsar, © BRCGL 2012 Hepat Mon. 2012;12(8):e6126